This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The interventions were one-year pharmacological treatment with orlistat (three times daily) in combination with a lowcalorie diet or a low-calorie diet alone and these were compared with no intervention.
Location/setting
Netherlands/primary care.
Methods

Analytical approach:
A well-validated Markov model, the Rijksinstituut voor Volksgezondheid en Milieu (RIVM) Chronic Disease Model, was used to estimate the life-long health benefits and costs of the interventions in the Dutch context. The time horizon was 80 years and the authors stated that the perspective of the health care system was adopted.
Effectiveness data:
The clinical estimates were derived from a variety of sources. The effectiveness of the interventions on weight loss was from a published meta-analysis. The incidence of, prevalence of, and mortality due to disease at different levels of BMI were derived from general practice registrations, national registries, and population surveys. The relative risks of morbidity and mortality by BMI were from observational studies. The details of the methods and the data used were reported in a separate study (van Baal, et al. 2006 , see 'Other Publications of Related Interest' below for bibliographic details) The main clinical outcomes were the proportion of individuals moving from obese to overweight due to the interventions and the average differences in diabetes and osteoarthritis prevalence due to the interventions.
Monetary benefit and utility valuations:
Disability weights for specific disease prevalences were obtained from the Dutch Burden of Disease Study. The RIVM Chronic Disease Model was used to estimate the BMI-related disease prevalence over time.
Measure of benefit:
Quality-adjusted life-years (QALYs) and life-years gained (LYG) were the measures of benefit. They were discounted at an annual rate of 1.5%.
